Bei GSK und ganz besonders im Geschäftsbereich Specialty Care ist unser oberstes Ziel der Beitrag zu einer bestmöglicher Patientenversorgung. Und diese fängt oft schon beim Zugang zur richtigen, innovativen Therapie an. Im Bereich der eosinophilen Erkrankungen
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
About AppLovin AppLovin makes technologies that help businesses of every size connect to their ideal customers. The company provides end-to-end advertising solutions for businesses to reach, monetize and grow their global audiences. For more information about
We are seeking an experienced All Source Analyst to support the Data Effects Cell (DEC) in delivering timely, accurate, and operationally relevant analytical products to U.S. Army Special Operations Command (USASOC) and partner force units operating